Oppenheimer assumed coverage on shares of OnKure Therapeutics (NASDAQ:OKUR – Free Report) in a research report report published on Thursday morning, Marketbeat.com reports. The brokerage issued an outperform rating and a $35.00 price objective on the stock.
OnKure Therapeutics Stock Down 3.1 %
OKUR stock opened at $18.42 on Thursday. The stock has a market cap of $61.52 million, a price-to-earnings ratio of -1.10 and a beta of 0.21. OnKure Therapeutics has a 12-month low of $9.80 and a 12-month high of $86.70.
About OnKure Therapeutics
See Also
- Five stocks we like better than OnKure Therapeutics
- Retail Stocks Investing, Explained
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- P/E Ratio Calculation: How to Assess Stocks
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- Canada Bond Market Holiday: How to Invest and Trade
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for OnKure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OnKure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
